– USA, NJ – Zoetis Inc. (NYSE: ZTS) announced the election of Dr. Mark Stetter (DVM) to its Board of Directors, effective on May 21, 2025, bringing extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine.
“We are pleased to welcome Dr. Mark Stetter to Zoetis’ Board of Directors, and we look forward to the contributions he will make as we continue to advance the animal health industry and deliver innovation to our customers,” said Board Chair Michael McCallister.
Dr. Mark Stetter will also join the Quality and Innovation Committee.
About Dr. Mark Stetter
Dr. Mark Stetter has served as Dean of the University of California, Davis School of Veterinary Medicine since 2021. In this role, he oversees all aspects of the school, including education, research, veterinary hospitals, animal health diagnostic labs, centers, and institutes. He was Dean and Professor at the College of Veterinary Medicine and Biomedical Sciences at Colorado State University from 2012 until 2021. Before joining higher education, he held various roles at The Walt Disney Company, The Bronx Zoo/Wildlife Conservation Society, and the Audubon Nature Institute.
“I am incredibly grateful for the opportunity to join Zoetis’ Board of Directors,” said Dr. Mark Stetter. “As a veterinarian I’ve seen firsthand the impact the company’s innovative products have on animals, and I look forward to bringing my professional expertise and passion for animal health to Zoetis as they continue to advance care for the industry.”
Dr. Stetter holds a Doctor of Veterinary Medicine and a Bachelor of Science degree in biochemistry and chemistry from the University of Illinois at Champaign-Urbana.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics, and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees.
For more: https://www.zoetis.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.